BriaCell Therapeutics Corp
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- William V. Williams
- Full Time Employees
- 17
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Bellevue Centre West Vancouver BC Canada V7T 2X1
- IPO Date
- Aug 13, 2012
- Website
- briacell.com
- Similar Companies
- Business
- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is a clinical-stage immuno-oncology biotechnology company that develops novel targeted cell-based immunotherapies for cancer treatment; its lead product candidate, Bria-IMT, a patented off-the-shelf immunotherapy, is evaluated in a pivotal Phase 3 combination study with an immune checkpoint inhibitor for metastatic breast cancer, which has received FDA Fast Track designation; the company is also advancing Bria-OTS and Bria-OTS+, next-generation personalized off-the-shelf immunotherapy platforms expressing multiple HLA types to match over 99% of patients via simple saliva testing, in Phase 1/2 bucket trials initially for breast cancer with planned expansions to prostate, lung, and melanoma, including Bria-PROS+ for prostate cancer scheduled to enter the clinic in the first half of 2025. BriaCell Therapeutics operates in the immunotherapy segment of the biotechnology industry, targeting advanced solid tumors primarily in breast and prostate cancer patients who are heavily pre-treated, CPI-resistant, or have central nervous system metastases; it maintains collaborations with the National Cancer Institute including a Small Business Innovation Research grant and partnerships such as with Memorial Sloan Kettering's Therapeutics Accelerator and New York Cancer & Blood Specialists for clinical expansion; the company holds a license from the University of Maryland for soluble CD80 technology. Founded in 2014 and headquartered in West Vancouver, British Columbia, Canada, with additional operations in Philadelphia, Pennsylvania, BriaCell Therapeutics recently closed a $5.0 million registered direct offering in May 2024 and priced a $13.8 million public offering in April 2025 to fund its Phase 3 study, R&D, and general corporate purposes; it added three cancer centers to its Phase 3 trial, initiated patient enrollment in the Bria-OTS Phase 1/2 bucket trial, received positive Data Safety Monitoring Board recommendations, and plans presentations of Phase 2 survival and Phase 3 biomarker data at the 2025 San Antonio Breast Cancer Symposium.
Company News
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
BriaCell Therapeutics Announces Closing of Offering
BriaCell Presents Positive Clinical Data at ASCO 2026
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Therapeutics Announces Pricing of Offering
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study